Delayed diagnosis of multiple sclerosis in a low prevalence country.

被引:19
作者
Cardenas-Robledo, Simon [1 ,2 ,3 ]
Lopez-Reyes, Lorena [1 ,3 ]
Arenas-Vargas, Laura Estefania [2 ,3 ]
Carvajal-Parra, Michael Steven [4 ]
Guio-Sanchez, Claudia [1 ,3 ]
机构
[1] Univ Nacl Colombia, Multiple Sclerosis Res Grp, Dept Neurol, MS Ctr, Bogota 111321, Colombia
[2] Univ Nacl Colombia, Multiple Sclerosis Res Grp, Dept Nursing, MS Ctr, Bogota, Colombia
[3] Univ Nacl Colombia, Multiple Sclerosis Res Grp, Dept Neurol, Bogota, Colombia
[4] Natl Univ Hosp Colombia, Dept Stat, Bogota, Colombia
关键词
Multiple sclerosis; diagnosis; delayed diagnosis; observational study; diagnostic delay; CRITERIA; COMORBIDITY; GUIDELINES; PANEL;
D O I
10.1080/01616412.2020.1866374
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Early diagnosis and treatment of multiple sclerosis (MS) is crucial to avoid future disability. The factors that influence diagnostic delay in low prevalence settings have been poorly studied. Objectives: To evaluate the factors associated with a delayed diagnosis of MS after the symptomatic onset. Methods: Clinical records of confirmed MS patients were reviewed. Diagnostic delay was calculated by subtracting the date of onset from the date of diagnosis and categorized as early and delayed, when below and above than 1 year. Logistic regression was performed to evaluate the likelihood of a delayed diagnosis according to age at first symptom, gender, type of the first symptom, progressive vs relapsing onset, diagnostic criteria prevailing at the time of symptom onset, comorbidities, and family history of MS. Results: Data of 525 (95.6%) from a cohort of 549 patients were analyzed. About 69.1% were women. The mean age was 43.2 years. About 86.3% had relapsing-remitting MS. The mean overall diagnostic delay was 3.07 years. About 45.7% of the patients had a delayed diagnosis, and it was dependent on the symptom and the diagnostic criteria prevailing at the onset. Multivariate logistic regression showed onset during the Schumacher (OR = 10.03 [95%CI 1.30-77.1], p = 0.027) and Poser (OR = 4.26 [95%CI 1.25-15.15], p = 0.021) years were associated with delayed MS diagnosis. Conclusions: MS onset before the McDonald diagnostic criteria era is associated with delayed diagnosis.
引用
收藏
页码:521 / 527
页数:7
相关论文
共 36 条
[1]   Diagnostic Delay of Multiple Sclerosis in a Portuguese Population [J].
Aires, Ana ;
Barros, Ariana ;
Machado, Celia ;
Fitas, Diogo ;
Cacao, Gongalo ;
Pedrosa, Rui ;
Cerqueira, Joao ;
Perdigao, Sandra ;
da Silva, Ana Martins ;
Vale, Jose ;
Sa, Maria Jose ;
Andrade, Carlos .
ACTA MEDICA PORTUGUESA, 2019, 32 (04) :289-294
[2]   How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis [J].
Barin, Laura ;
Kamm, Christian P. ;
Salmen, Anke ;
Dressel, Holger ;
Calabrese, Pasquale ;
Pot, Caroline ;
Schippling, Sven ;
Gobbi, Claudio ;
Mueller, Stefanie ;
Chan, Andrew ;
Rodgers, Stephanie ;
Kaufmann, Marco ;
Ajdacic-Gross, Vladeta ;
Steinemann, Nina ;
Kesselring, Juerg ;
Puhan, Milo A. ;
von Wyl, Viktor .
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (04) :489-500
[3]   Early versus later treatment start in multiple sclerosis: a register-based cohort study [J].
Chalmer, T. A. ;
Baggesen, L. M. ;
Norgaard, M. ;
Koch-Henriksen, N. ;
Magyari, M. ;
Sorensen, P. S. .
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (10) :1262-E110
[4]  
Confavreux C, 2014, HAND CLINIC, V122, P343, DOI 10.1016/B978-0-444-52001-2.00014-5
[5]   Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study) [J].
Fernandez, O. ;
Fernandez, V. ;
Arbizu, T. ;
Izquierdo, G. ;
Bosca, I. ;
Arroyo, R. ;
Garcia Merino, J. A. ;
de Ramon, E. .
JOURNAL OF NEUROLOGY, 2010, 257 (09) :1500-1507
[6]  
Filippi M, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/s41572-018-0041-4, 10.1038/s41572-018-0046-z]
[7]   Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study [J].
Guillemin, Francis ;
Baumann, Cedric ;
Epstein, Jonathan ;
Kerschen, Philippe ;
Garot, Teresa ;
Mathey, Guillaume ;
Debouverie, Marc .
NEUROEPIDEMIOLOGY, 2017, 48 (3-4) :179-187
[8]   Alemtuzumab CARE-MS I 5-year follow-up Durable efficacy in the absence of continuous MS therapy [J].
Havrdova, Eva ;
Arnold, Douglas L. ;
Cohen, Jeffrey A. ;
Hartung, Hans-Peter ;
Fox, Edward J. ;
Giovannoni, Gavin ;
Schippling, Sven ;
Selmaj, Krzysztof W. ;
Traboulsee, Anthony ;
Compston, D. Alastair S. ;
Margolin, David H. ;
Thangavelu, Karthinathan ;
Rodriguez, Claudio E. ;
Jody, Darlene ;
Hogan, Richard J. ;
Xenopoulos, Panos ;
Panzara, Michael A. ;
Coles, Alasdair J. .
NEUROLOGY, 2017, 89 (11) :1107-1116
[9]  
Jiménez-Pérez Cheryl E, 2015, Acta Neurol Colomb., V31, P385
[10]   Long-term effects of fingolimod in multiple sclerosis The randomized FREEDOMS extension trial [J].
Kappos, Ludwig ;
O'Connor, Paul ;
Radue, Ernst-Wilhelm ;
Polman, Chris ;
Hohlfeld, Reinhard ;
Selmaj, Krzysztof ;
Ritter, Shannon ;
Schlosshauer, Rolf ;
von Rosenstiel, Philipp ;
Zhang-Auberson, Lixin ;
Francis, Gordon .
NEUROLOGY, 2015, 84 (15) :1582-1591